A Phase Iia, Randomized, Double Blind, Placebo Controlled, Three-treatment, Two-period Crossover Study Of The Efficacy And Safety Of Two Doses Of Pf-03654746 In Adults With Attention Deficit Hyperactivity Disorder
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2016
At a glance
- Drugs PF 3654746 (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Pfizer
- 08 Dec 2008 Actual patient number (69) added as reported by ClinicalTrials.gov.
- 08 Dec 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 08 Dec 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.